Polygenic Risk Score vs Monogenic Genetic Testing: Understanding Two Different Dimensions of Genetic Risk

The Evolution of Genetic Risk Assessment

Genetic testing has transformed modern medicine, enabling clinicians to move beyond symptom-based diagnosis toward biologically informed care. However, not all genetic tests are the same. Broadly, genetic risk assessment can be divided into two major categories: monogenic testing and polygenic risk scoring. While both evaluate inherited DNA variations, they differ fundamentally in purpose, interpretation, predictive power, and clinical application. Understanding the distinction is essential for clinicians, policymakers, and informed patients navigating precision medicine.

What Is Monogenic Genetic Testing?

Monogenic genetic testing focuses on identifying mutations in a single gene that directly cause or strongly predispose an individual to a specific disease. These conditions typically follow Mendelian inheritance patterns — autosomal dominant, autosomal recessive, or X-linked.

Examples include BRCA1 and BRCA2 mutations associated with hereditary breast and ovarian cancer, mutations in LDLR linked to familial hypercholesterolemia, and variants in MLH1 or MSH2 related to Lynch syndrome. In these cases, a pathogenic mutation carries a relatively high penetrance, meaning the likelihood of developing disease is significantly elevated compared to the general population.

Monogenic tests usually provide a binary outcome: a pathogenic mutation is either detected or not detected. When a disease-causing mutation is identified, the clinical implications are often clear — intensified screening, prophylactic surgery, cascade testing for family members, or targeted therapy may be recommended.

What Is a Polygenic Risk Score (PRS)?

In contrast, a Polygenic Risk Score evaluates the combined effect of numerous common genetic variants across the genome. Most common diseases — such as coronary artery disease, type 2 diabetes, breast cancer, and Alzheimer’s disease — are not caused by a single gene mutation but by the additive influence of many variants, each contributing a small increment of risk.

PRS aggregates these small-effect variants using weights derived from large genome-wide association studies. The result is a relative risk estimate that positions an individual along a risk distribution compared to the population. Unlike monogenic testing, PRS does not identify a specific mutation responsible for disease. Instead, it quantifies inherited susceptibility on a continuum — low, intermediate, or high genetic risk.

Deterministic vs Probabilistic Risk

One of the most important differences between monogenic testing and PRS lies in the nature of risk interpretation. Monogenic mutations are often considered more deterministic. If a high-penetrance mutation is present, the risk increase can be substantial and clinically actionable.

PRS, on the other hand, is probabilistic. A high polygenic score increases the likelihood of developing a disease but does not guarantee it. Similarly, a low score reduces relative risk but does not eliminate the possibility of disease. Environmental exposures, lifestyle factors, epigenetic influences, and gene–environment interactions play critical roles in determining whether genetic predisposition manifests clinically.

Thus, monogenic testing often answers the question: “Is there a single, strong genetic driver of this disease?”PRS answers a different question: “Based on cumulative genetic background, how predisposed is this individual compared to others?”

Differences in Clinical Application

Monogenic testing is commonly used in diagnostic or high-risk contexts. It is particularly valuable when there is a strong family history, early-onset disease, or characteristic clinical features suggesting a hereditary syndrome. The results may guide specific therapeutic decisions, such as the use of PARP inhibitors in BRCA-mutated cancers or aggressive lipid management in familial hypercholesterolemia.

PRS, in contrast, is primarily used in preventive and population health settings. Because it can be assessed at any age, PRS enables early risk stratification before symptoms arise. For example, individuals with high PRS for coronary artery disease may benefit from earlier lifestyle interventions or preventive therapy. In oncology, PRS can refine screening strategies for individuals who do not carry high-penetrance mutations but still have elevated inherited risk.

Rather than replacing monogenic testing, PRS complements it. Together, they provide a more comprehensive picture of inherited risk.

Scope of Impact Across Populations

Monogenic disorders are relatively rare in the general population, although their impact on affected individuals and families can be profound. In contrast, polygenic risk influences a much larger proportion of the population because common diseases are driven by complex genetic architecture.

While only a small percentage of breast cancer cases are attributable to high-penetrance mutations such as BRCA1/2, a substantial proportion of cases are influenced by polygenic background combined with environmental factors. This distinction highlights why PRS has broad potential in population-level risk stratification.

Limitations and Considerations

Both approaches have limitations. Monogenic testing may identify variants of uncertain significance, which require careful interpretation and sometimes additional functional studies. Not all individuals with pathogenic mutations will develop disease due to incomplete penetrance.

PRS faces challenges related to population diversity, as many large genetic studies have historically been conducted in European ancestry cohorts. Applying PRS across diverse ethnic groups requires well-validated, population-specific datasets to ensure accuracy and equity. Furthermore, communicating probabilistic risk requires careful genetic counseling to avoid misunderstanding.

Integration in the Era of Precision Medicine

The future of genetic risk assessment lies not in choosing between monogenic testing and PRS, but in integrating both. For certain individuals, monogenic testing may identify high-impact mutations requiring immediate action. For the broader population, PRS provides a scalable approach to early risk stratification and preventive care.

In combination with lifestyle assessment, biomarkers, imaging, and multi-omics data, these tools move healthcare beyond reactive treatment toward predictive and preventive strategies.

Conclusion: Two Tools, One Goal

Monogenic genetic testing and Polygenic Risk Scores represent two complementary dimensions of inherited risk assessment. Monogenic testing identifies rare but high-impact mutations with clear clinical pathways. PRS captures the subtle, cumulative genetic architecture underlying common diseases.

Together, they reflect the evolution of genomic medicine — from identifying single genetic drivers to understanding the complex biological networks that shape disease risk. In doing so, they advance the shared goal of precision medicine: delivering the right intervention to the right individual at the right time.